-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Big Pharma Might Already Have Sights on Abbott Spinoff
Abbott's Humira is a dollar-printing temptation for several companies, but Pfizer's tofacitinib could change the rheumatoid arthritis drug landscape.
Should You Buy the Dow — Merck
Merck is a strong, old company with a good dividend -- it suits retirement accounts fine, but regular traders might want to keep their distance.
Is Abbott’s Spinoff the Beginning of a Trend?
A look at Abbott Labs' (ABT) breakup indicates splitting up may be good medicine for other diversified health care companies.
Johnson & Johnson, Forest Labs Will Make You Sick
Johnson & Johnson beat expectations but its profits were down; Forest Labs missed and has a plunging profit forecast. Investors should be wary of both pharma options.
Pfizer Crafting a Post-Patent Game Plan
As its Lipitor patent nears expiration, Pfizer considers new uses for Lyrica, its popular painkiller for fibromyalgia.
Should You Buy the Dow — Johnson & Johnson
Johnson & Johnson is protected by a diverse product line and sitting on a heap of cash. But JNJ stock already is on the high side of valuation, making this a tough pick.
7 Pharma Stocks to Sell, STAT
Pharmaceutical stocks are theoretically recession-proof. Still, not all pharma companies are equal. Here are seven clear losers to toss.
Heed the Red Flags at Amedisys
Congressional scrutiny of home health care specialist Amedisys, along with lowered guidance, are sure-fire signs that investors should proceed with care.
3 Winners to Expect This Earnings Season
Earnings season has begun -- and these three highly-rated stocks are expected to hit it out of the park.
10 Big Pharma Stocks to Buy
Pharmaceutical stocks and drugmakers are theoretically recession-proof businesses. Still, not all pharma companies are created equal. Here are 10 clear winners
Lilly Should Survive Patent Loss on Blockbuster Drug Zyprexa
On Oct. 23, Eli Lilly will wave goodbye to the U.S. patent on the best-selling drug in its 135-year history. Here's why investors shouldn't be worried.
Bristol-Myers Shares Are a Blue-Chip Keeper
The pharmaceutical giant's stock has posted several new highs and offers an attractive dividend yield.
Illumina Shares Take a Tumble
The biotech's stock hits the skids after the company warns revenue will take a hit.
Onyx’s Staying Power Tied to New Cancer Drug Carfilzomib
Onyx needs the financial boost from its multiple myeloma-treating drug to ween it off dependence on an uneasy partnership with Bayer.
Suit Asks J&J CEO to Return Part of 2010 Pay
J&J CEO Bill Weldon’s gains don’t reflect shareholder pain, some stakeholders say.
Study Results Boost Analyst’s Forecast for Novartis Drug
An analyst boosts his forecast for Novartis' Afinitor based on its promise as a treatment for breast cancer.
FDA’s Easing on Obesity Drugs Could Fatten Investor Wallets
Vivus and Orexigen's diet-pill hopes are resurrected as the FDA relaxes its stance against obesity treatments.
9 Healthy Biotech Buys
Baby boomers are getting older and in need of more and more treatments, thus the race for the next big blockbuster drug. Smaller biotechs are cashing in.
